Five Prime Therapeutics Inc. (NASDAQ:FPRX) has received a consensus recommendation of “Buy” from the seven analysts that are currently covering the firm. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $54.00.

A number of research analysts recently weighed in on FPRX shares. Credit Suisse Group AG reiterated a “buy” rating on shares of Five Prime Therapeutics in a report on Tuesday, July 12th. Jefferies Group set a $60.00 target price on Five Prime Therapeutics and gave the company a “buy” rating in a report on Friday, August 5th. Finally, Leerink Swann reiterated an “outperform” rating and issued a $58.00 target price (up previously from $45.00) on shares of Five Prime Therapeutics in a report on Monday, August 8th.

In other news, Director Peder Jensen sold 12,195 shares of Five Prime Therapeutics stock in a transaction dated Wednesday, July 27th. The stock was sold at an average price of $49.50, for a total transaction of $603,652.50. Following the sale, the director now directly owns 12,195 shares of the company’s stock, valued at $603,652.50. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director William R. Ringo sold 500 shares of Five Prime Therapeutics stock in a transaction dated Monday, August 1st. The stock was sold at an average price of $50.77, for a total value of $25,385.00. Following the sale, the director now directly owns 500 shares in the company, valued at $25,385. The disclosure for this sale can be found here. 5.30% of the stock is owned by company insiders.

Several hedge funds have recently made changes to their positions in the company. Williams Jones & Associates LLC raised its stake in shares of Five Prime Therapeutics by 87.3% in the second quarter. Williams Jones & Associates LLC now owns 11,066 shares of the company’s stock worth $458,000 after buying an additional 5,159 shares during the last quarter. Sterling Capital Management LLC acquired a new stake in shares of Five Prime Therapeutics during the second quarter worth about $546,000. Schwab Charles Investment Management Inc. raised its stake in shares of Five Prime Therapeutics by 215.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 143,992 shares of the company’s stock worth $5,955,000 after buying an additional 98,353 shares during the last quarter. Legal & General Group Plc raised its stake in shares of Five Prime Therapeutics by 5.4% in the second quarter. Legal & General Group Plc now owns 4,077 shares of the company’s stock worth $169,000 after buying an additional 208 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY raised its stake in shares of Five Prime Therapeutics by 10.6% in the second quarter. Metropolitan Life Insurance Co. NY now owns 19,875 shares of the company’s stock worth $822,000 after buying an additional 1,908 shares during the last quarter. 86.49% of the stock is currently owned by institutional investors and hedge funds.

Five Prime Therapeutics (NASDAQ:FPRX) traded down 2.15% during midday trading on Wednesday, hitting $50.89. The company had a trading volume of 161,824 shares. The stock has a 50 day moving average of $47.48 and a 200 day moving average of $43.86. Five Prime Therapeutics has a 52-week low of $14.70 and a 52-week high of $55.00. The firm has a market cap of $1.37 billion, a price-to-earnings ratio of 5.72 and a beta of 4.51.

Five Prime Therapeutics (NASDAQ:FPRX) last issued its earnings results on Thursday, August 4th. The company reported ($0.49) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.56) by $0.07. Five Prime Therapeutics had a return on equity of 69.59% and a net margin of 63.88%. The firm had revenue of $9.23 million for the quarter, compared to analysts’ expectations of $6.38 million. During the same quarter last year, the firm earned ($0.45) earnings per share. The firm’s revenue for the quarter was up 46.1% compared to the same quarter last year. On average, analysts anticipate that Five Prime Therapeutics will post ($2.37) EPS for the current year.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations.

5 Day Chart for NASDAQ:FPRX

Receive News & Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.